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Identity 
Other names: PLK; STPK13 (SERINE/THREONINE 
PROTEIN KINASE 13) 
HGNC (Hugo): PLK1 
Location: 16p12.1 
Local order: Genes flanking PLK1 in centromere to 
telomere direction on 16p12 are: 
UBPH, 16p12, similar to ubiquitin binding protein 
NDUFAB1, 16p12.1, NADH dehydrogenase 
(ubiquinone) 1, alpha/beta subcomplex, 1,8kDa 
FLJ21816, 16p12.1, hypothetical protein FLJ21816 
MGC3248, 16p12.1, dynactin 4 
PLK1, 16p12.1, polo-like kinase 1 (Drosophila) 
LOC388226, 16p12.1, similar to endoplasmic 
reticulum (ER) to nucleus signaling 2; inositol-
requiring 1 (Yeast homologue) 
LOC63928, 16p12.1, hepatocellular carcinoma antigen 
gene 520 
PRKCB1, 16p11.2, protein kinase C, beta 1 
CACNG3, 16p12-p13.1, calcium channel, voltage-
dependent, gamma subunit 3 
Note 
Polo like kinases belong to serine/threonine kinases 
that are conserved from yeast to human cells. Polo like 
kinases exhibit important roles in key cellular events 
regulating cell cycle progression and cell division such 
as centrosome maturation, cdc2  
activation, mitotic spindle formation, regulation of the 
anaphase promoting complex, chromosome 
segregation, cytokinesis, DNA damage response 
pathways and apoptosis. 
DNA/RNA 
Description 
PLK1 mRNA spans approximately 11.5 kb and has 10 
exons. The sizes of the exons 1 to 10 are 461, 169, 145, 
94, 220, 156, 78, 155, 183 and 508 bps. 
Transcription 
PLK1 mRNA (NM_005030) is 2204 bp. PLK1 
expression is believed to reach its peak value in mitosis 
in the cell cycle. It is highly expressed in actively 
proliferating tissues such as those in the placenta, 
spleen, ovary, and testis. High expression of PLK1 is 
also detected in various neoplastic tissues. Northern 
blot analysis reveals low or undetectable levels of 
PLK1 transcript in most other adult tissues (e.g.: brain, 
thymus, liver, lung, pancreas, heart, kidney, stomach, 
intestine and skin). 
Pseudogene 
Mouse Plk gene maps to Chromosome 7 and the 
processed pseudogene to mouse Chromosome 5. No 




The alignment of PLK1 mRNA (NM_005030) to its genomic sequence NC_000016). 
 











Protein consists of 603 amino acids and is 66kDa. In 
addition to the N-terminus kinase domain, there are two 
conserved polo-box regions of 30 amino acids at the C-
terminus. Kinase activity is regulated at least in part, by 
the polo-boxes that are functionally important for b th 
auto-inhibition and sub-cellular localization. 
Expression 
PLK1 protein becomes a target of the anaphase-
promoting complex/cyclosome and is degraded by the 
ubiquitin-proteasome pathway as cells exit mitosis. 
Localisation 
During interphase, PLK1 localizes to centrosomes. In 
early mitosis, it associates with mitotic spindle poles. A 
recombinant GFP-PLK1 protein localizes to 
centromere/kinetochore region, suggesting a possible 
role for chromosome separation. 
Function 
PLK1 is believed to be involved in the regulation of 
key steps during cell division, DNA damage repair 
pathways, apoptosis, and the progression of the cell 
cycle. 
PLK1 has roles in the activation of cdc2 through cdc25 
and direct phosphorylation of cyclin B1, through which 
MPF (mitosis promoting factor) is activated so that 
mitosis can start. 
Microinjection of PLK1 antibodies causes failure of g-
tubulin recruitment to the centrosomes. This failure 
results in immature centrosomes and monopolar spindle 
formation. Similar microinjection experiments in cell 
lines (transformed HeLa and non-immortalized Hs68 
fibroblasts) result in a marked inhibition of cell cycle 
progression. 
PLK1 also has a possible role during cytokinesis based 
on the observation that PLK1 interacts and co-localizes 
with a kinesin related motor protein (CHO1/MKLP-1) 
at the interzone during anaphase and the mid-body 
during telophase and cytokinesis. 
Evidence suggests that BRCA2 is a substrate of PLK1 
both in response to DNA damage and during normal 
cell cycle progression. This suggests a role for PLK1 in 
regulating DNA damage repair. 
Other studies have shown that the loss of PLK1 
expression can induce pro-apoptotic pathways and 
inhibit growth. 
Based on yeast and murine studies of meiosis, human 
PLK1 may also have a regulatory function in meiosis. 
S. cerevisiae polo kinase CDC5 is required to 
phosphorylate and remove meiotic cohesion during the 
first cell division. In CDC5 depleted cells, kinetochores 
are bioriented during meiosis I, and Mam1, a protein 
essential for coorientation, fails to associate with 
kinetochores. CDC5 is believed to have roles in sister-
kinetochore coorientation and chromosome segregation 
during meiosis I. 
Homology 
P.troglodytes: PLK1, polo-like kinase, XP_510879.1, 
735 aa. 
M.musculus: Plk1, polo-like kinase 1 (Drosophila), 
NP_035251.2, 603 aa. 
R.norvegicus: Plk1, polo-like kinase 1 (Drosophila), 
NP_058796.1, 603 aa. 
D.melanogaster: polo, polo, NP_524179.2, 576 aa 
C.elegans: plk-1 PoLo Kinase, NP_741243.1, 649 aa. 
S.cerevisiae: CDC5, NP_013714.1, 705 aa. 
Implicated in 
Note 
Increased PLK1 levels are detected in a variety of 
cancers. 
Disease 
Increased PLK1 transcript has been detected in a 
variety of tumor types including esophageal, head an  
neck squamous cell, liver, lung and breast carcinomas. 
Immunohistochemical studies also demonstrate 
increased PLK1 protein levels in melanomas, breast, 
ovarian, prostate cancers, and head, neck squamous cell 
carcinomas. 
Prognosis 
Statistically significant correlations between increased 
PLK1 expression and decreased patient survival 
suggest that PLK1 is a negative prognostic indicator for 
some types of cancer.  
For example, 
- In prostate cancer, PLK1 overexpression is linked to 
higher tumor grades; 
- In non-Hodgkin's lymphomas, PLK1 overexpression 
reflects malignancy potentials. In hepatoblastomas, 
ovarian, colorectal cancers and melanomas, PLK1 
overexpression suggests PLK1 to be a poor-prognostic 
indicator. 
Oncogenesis 
Oncogenic properties of PLK1 are believed to be due to 
its role in driving cell cycle progression. Supporting 
evidence comes from the overexpression studies of 
PLK1 in NIH3T3 cell line. These cells become capable 
of forming foci and growing in soft agar and more 
importantly, these cells can form tumors in nude mice 
due to PLK1 overexpression. 
PLK1 has also been linked to known pathways that are 
altered during the neoplastic transformation. 
Retinoblastoma tumor suppressor (RB) pathway 
activation results in the repression of PLK1 promoter in 
a SWI/SNF chromatin remodeling complex dependent 
manner. In case of RB inactivation, PLK1 expression 
seems to be deregulated. This new finding suggests tha  
PLK1 may be a target of the retinoblastoma tumor 
suppressor (RB) pathway. 
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Moreover, PLK1 seems to be involved in the tumor 
suppressor p53 related pathways. Evidence suggests 
that PLK1 can inhibit transactivation and pro-apoptotic 
functions of p53 function by physical interaction ad 
phosphorylation. 
In addition to PLK1¹s role in normal cell cycle 
regulation, its connection to such known tumor 
suppressors may be crucial for the tumorigenesis 
processes. 
To be noted 
Note 
A study also suggests that PLK1 protein cannot be 
detected in normal brain tissue but it can be detect d in 
brain tissues from Alzheimer¹s disease patients. 
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